Clinical Trial Update: Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial updating Elbasvir/Grazoprevir for chronic hepatitis C infection has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir (elbasvir/grazoprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HCV Infection | Phase 2 | Status: COMPLETED | Results posted: 2020-08-17